PPT-Ledipasvir-Sofosbuvir + RBV in Decompensated Cirrhosis or Post-Liver Transplantation

SOLAR2 Source Manns M et al Lancet Infect Dis 20161668597 Treatment Naïve and Treatment Experienced Phase 2 LedipasvirSofosbuvir Ribavirin in Advanced Liver Disease SOLAR2 Features. AYURVEDIC . TREATMENT . Dr. . Vikram. . Chauhan. is One of the most . Promising . Ayurvedic. doctors in the world. and a senior consultant physician from India. . He has 12 years of international exposure & . Kelsey Conrad. Annelise. . Chmelik. September 24, 2013. the . Liver. Largest organ in the body. Extremely complex organ. Filters harmful substances from the blood. Makes substances that digests food. (. Epclusa. ). Prepared by. : H. Nina Kim, MD MSc and David . Spach. , MD. Last . Updated: . July . 8, . 2016. Background and Dosing. Sofosbuvir-Velpatasvir. (. Epclusa. ). Sofosbuvir-Velpatasvir. (. ION-4. Phase . 3. Treatment. Naïve and Treatment . Experienced. Naggie. S, . et al. . N . Engl. J Med 2015;378:705-13.. HIV Coinfection. Source: . Naggie. S, et al. N . Engl. J Med 2015;378:705-13.. Harvoni. ). Prepared by: . David H. Spach, MD and H. Nina Kim, MD MSc. Last . Updated: . December 15, 2015. Background and Dosing. Ledipasvir-Sofosbuvir (. Harvoni. ). Ledipasvir-Sofosbuvir (. Harvoni. Jon . Bishop. Consultant Paediatric Gastroenterology. Starship Children’s Hospital. CF Liver Disease. Single . commonest non-respiratory cause of CF mortality. Various manifestations. Neonatal cholestasis. rd. DAA in HCV Genotype 1 . NIAID SYNERGY: Genotype 1. Phase . 2. Treatment. . Naïve . (unfavorable baseline treatment . characteristics). Kohli. . A, et al. . Lancet. 2015:385:1107-13.. Source. ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . Medical Director, Austin Hepatitis Center. 1. Hepatitis C & PCP’s. 2. LACK OF AWARENESS. LACK OF APPROPRIATE ACTION. Expand Quantitative Landscape Study – Oct 2013 [Gilead Sciences]. 35-50% of PCP believe HCV can be cured. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. Duke University School of Medicine. Durham, North Carolina. Treatment of Hepatitis C in Patients . With . Cirrhosis. Recorded on . 10/24/14. Disclosure. Dr. Muir has received grants and research support from . ASTRAL-4. Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.. Treatment Naïve and Treatment Experienced, Phase 3. Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis. ASTRAL-4: Study Features.